Cargando…

Advances in immune checkpoint inhibitors induced-cardiotoxicity

Immune checkpoint inhibitors (ICIs) are approved as the first-line drug for treating many cancers and has shown significant survival benefits; however, it also causes immune-related adverse events (irAEs) while activating the immune system, involving multiple organs. Among them, cardiovascular immun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiang, Peng, Wenying, Wu, Jiao, Yeung, Sai-Ching Jim, Yang, Runxiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995967/ https://www.ncbi.nlm.nih.gov/pubmed/36911712 http://dx.doi.org/10.3389/fimmu.2023.1130438

Ejemplares similares

Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis
por: Liu, Maobai, et al.
Publicado: (2022)

Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity
por: Yang, Fang, et al.
Publicado: (2017)

Cardiotoxicity of immune checkpoint inhibitors
por: Varricchi, Gilda, et al.
Publicado: (2017)

Cardiotoxicity of Immune Checkpoint Inhibitors
por: Patel, Rushin P., et al.
Publicado: (2021)

Immune Checkpoint Inhibitors—Associated Cardiotoxicity
por: Li, Chenghui, et al.
Publicado: (2022)

Cardiotoxicity from immune checkpoint inhibitors
por: Michel, Lars, et al.
Publicado: (2019)

The Potential Cardiotoxicity of Immune Checkpoint Inhibitors
por: Nardi Agmon, Inbar, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors Related to Cardiotoxicity
por: Chen, Ru, et al.
Publicado: (2022)

Cardiotoxicity Associated with Immune Checkpoint Inhibitors
por: Minegishi, Shintaro, et al.
Publicado: (2023)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Managing cardiotoxicity associated with immune checkpoint inhibitors
por: Upadhrasta, Sireesha, et al.
Publicado: (2019)

Cardiotoxicity risk factors with immune checkpoint inhibitors
por: Brumberger, Zachary L., et al.
Publicado: (2022)

Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers
por: Li, Ye, et al.
Publicado: (2021)

An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors
por: Esposito, Roberta, et al.
Publicado: (2021)

Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy
por: Rajha, Eva, et al.
Publicado: (2019)

Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment
por: Ganesh, Sridha, et al.
Publicado: (2022)

Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity
por: Guo, Xiaoxiao, et al.
Publicado: (2019)

A Systematic Review of Myocarditis Induced by Immune Checkpoint Inhibitors: How Concerning Is the Most Common Cardiotoxicity of Immune Checkpoint Inhibitors?
por: Moradi, Ali, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance
por: Mascolo, Annamaria, et al.
Publicado: (2021)

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
por: Zou, Xue-lin, et al.
Publicado: (2021)

Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response
por: Yang, Fei, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization
por: Urban, Hans, et al.
Publicado: (2022)

TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis
por: Liu, Xiaohang, et al.
Publicado: (2022)

A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors
por: lessomo, Fabrice Yves Ndjana, et al.
Publicado: (2023)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology
por: Liu, Zefan, et al.
Publicado: (2022)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer
por: Yan, Yi-Dan, et al.
Publicado: (2021)

Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression
por: Chen, Chao, et al.
Publicado: (2023)

Immune-related ureteritis and cystitis induced by immune checkpoint inhibitors: Case report and literature review
por: Li, Jun, et al.
Publicado: (2023)

Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis
por: She, Jianqing, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies
por: Xu, Shirley, et al.
Publicado: (2021)

Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies
por: Ronen, Daniel, et al.
Publicado: (2022)

Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022)

Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor‐associated cardiotoxicity
por: Liang, Lin, et al.
Publicado: (2023)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Case report: Brain metastasis necrosis with immune checkpoint inhibitors plus chemotherapy for advanced non-small cell lung cancer
por: Niu, Lishui, et al.
Publicado: (2022)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies
por: González-Navajas, Jose M., et al.
Publicado: (2021)

The Emerging Role of the Gut Microbiome in the Cancer Response to Immune Checkpoint Inhibitors: A Narrative Review
por: Araji, Ghada, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_krqef0tb88rtei6vkplb5d56el